Skip to content

EV / sales at other companies

Pfizer logo
PfizerPFE
3.5×+0.3×
Merck & Co. logo
Merck & Co.MRK
5.2×+1.2×
AbbVie logo
AbbVieABBV
7.5×+1.0×
Insmed logo
InsmedINSM
43×+4.8×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
14.1×+3.2×

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s EV / sales?
Innoviva, Inc. (INVA) reported EV / sales of 3.3× in Q1 2026.
How has Innoviva, Inc.'s EV / sales changed year-over-year?
Innoviva, Inc.'s EV / sales decreased by 3.5% year-over-year, from 3.4× to 3.3×.
What is the long-term trend for Innoviva, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Innoviva, Inc.'s EV / sales has grown at a -0.1% compound annual growth rate (CAGR), from 3× to 2.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.